Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
AstraZeneca
Leap Therapeutics, Inc.
Eisai Inc.
Ohio State University Comprehensive Cancer Center
Washington University School of Medicine
University of Oklahoma
Big Ten Cancer Research Consortium
Takeda
The Cleveland Clinic
R-Pharm
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center